Vest Financial LLC Acquires 1,059 Shares of Thermo Fisher Scientific Inc. $TMO

Vest Financial LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 23.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,499 shares of the medical research company’s stock after acquiring an additional 1,059 shares during the quarter. Vest Financial LLC’s holdings in Thermo Fisher Scientific were worth $2,667,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Highline Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 33 shares in the last quarter. Capital A Wealth Management LLC boosted its position in Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after buying an additional 66 shares during the last quarter. DiNuzzo Private Wealth Inc. increased its stake in shares of Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after buying an additional 61 shares during the period. HighMark Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the last quarter. Finally, Howard Hughes Medical Institute bought a new position in Thermo Fisher Scientific in the second quarter valued at about $33,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on TMO shares. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. Stifel Nicolaus increased their price objective on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a report on Friday, January 9th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. Finally, UBS Group upped their price objective on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $625.47.

Thermo Fisher Scientific Price Performance

TMO opened at $639.03 on Friday. The stock has a market cap of $240.09 billion, a P/E ratio of 36.92, a P/E/G ratio of 4.19 and a beta of 0.91. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company has a fifty day simple moving average of $589.96 and a 200 day simple moving average of $529.43.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.28 earnings per share. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has approved a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. The trade was a 7.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Frederick M. Lowery sold 6,912 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the sale, the executive vice president directly owned 14,367 shares of the company’s stock, valued at $8,360,731.98. This represents a 32.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 131,767 shares of company stock worth $76,467,793. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.